In section Newsroom

El-Sayed Triumphs in Michigan Senate Primary Against AIPAC Spending

Epidemiologist Abdul El-Sayed holds a narrow lead in the Michigan Democratic Senate primary, defying a historic $30 million intervention by AIPAC. While NBC has declared him the winner, The Associated Press maintains the race remains too close to call with 90% of the ballots currently tallied.

El-Sayed Triumphs in Michigan Senate Primary Against AIPAC Spending

With a lead of approximately 21,000 votes, El-Sayed’s campaign has become a focal point for the tension between grassroots progressive movements and deep-pocketed special interests. The contest stands as the most expensive Democratic primary in U.S. history, marked by an $11-to-$1 spending disadvantage for El-Sayed. Addressing supporters on election night, the candidate framed his performance as a rejection of corporate-backed influence, noting that despite the overwhelming financial onslaught, his movement remained standing.

A victory here represents a significant setback for AIPAC, which directed nearly half of all outside spending toward defeating the progressive challenger. Margaret DeReus of the IMEU Policy Project characterized the result as a signal that voters are distancing themselves from the lobby’s influence on foreign policy and military funding. Looking ahead, the Democratic nominee is set to face Republican Mike Rogers in the November general election.

Broader trends in the state suggest a wider appetite for progressive policy platforms. William Lawrence has secured the nomination in Michigan's 7th Congressional District, and state Representative Donavan McKinney maintains a lead over incumbent Shri Thanedar in the 13th District. Advocacy groups like RootsAction interpret these outcomes as a clear mandate for Medicare for All and a shift away from interventionist foreign policies.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!